Zacks Research Comments on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report released on Tuesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.05 per share for the year, down from their previous forecast of $0.07. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.80) per share.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Bank of America lowered Esperion Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, January 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $9.33.

Esperion Therapeutics Stock Down 0.3 %

Shares of ESPR traded down $0.01 on Thursday, reaching $3.11. The stock had a trading volume of 11,289,251 shares, compared to its average volume of 6,738,484. The firm has a 50-day moving average of $2.46 and a 200 day moving average of $1.86. The firm has a market capitalization of $575.51 million, a PE ratio of -1.47 and a beta of 0.84. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the previous year, the firm posted ($0.76) EPS.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. grew its stake in Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company's stock valued at $405,000 after purchasing an additional 225,767 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Esperion Therapeutics by 159.1% during the 3rd quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company's stock valued at $1,094,000 after acquiring an additional 685,733 shares during the last quarter. Simplicity Solutions LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth $30,000. Pinnacle Associates Ltd. increased its position in shares of Esperion Therapeutics by 15.7% in the 3rd quarter. Pinnacle Associates Ltd. now owns 289,123 shares of the biopharmaceutical company's stock worth $283,000 after purchasing an additional 39,285 shares during the last quarter. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth about $29,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.